Thyroiditis, Suppurative

OSAKA, Japan, April 25, 2024 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that it has made the following revisions to its dividend forecasts for the fiscal year ending March 31, 2024 (fiscal 2023; April 1, 2023 – March 31, 2024). The dividend forecasts were originally announced on May 10, 2023. 1. Revisions to Dividend Forecasts Dividends per share (yen) End of second quarter Year end Annual Previous forecast ― 75.00 150.00 Revised forecast ― 85.00 160.00 Current fiscal year 75.00 Previous fiscal year (ended March 31, 2023) 60.00 75.00 135.00 2. Reasons for Revisions to Dividend Forecasts Shionogi strives to maximize corporate value by balancing investment in growth and shareholder return, and to share the benefits of mid-to-long term profit growth with shareholders. Consistent with that intention, Shionogi plans to stably increase its consolidated dividends, with a DOE of 4% or higher as an index. In fiscal 2023, Shionogi announced our new revision to our Medium-term Business Plan, STS2030. Accordingly, we have continued to enhance our strengths as a drug-discovery-based pharmaceutical company, while transforming ourselves into a HaaS company that provides a broader integrated range of healthcare products and services, providing new value to society. We have been progressing these efforts in order to offer more comprehensive solutions to the healthcare challenges faced by patients and society. As a result, we have expanded the sales of Xocova, a COVID-19 treatment drug, and of our influenza franchise, mainly Xofluza, in Japan. By establishing multi-drug respiratory infectious disease portfolio, we have been able to record stable profits throughout the year and have stabilized our acute infectious disease business which is considered to be easily affected by shifting epidemics. We are also working towards the realization of early diagnosis and early treatment (“test and treat”) to ensure that infectious disease drugs promptly reach the patients who need them. In the overseas business, in addition to our own sales growth with cefiderocol, we have made great progress in expanding access to this important drug by utilizing partnerships to significantly increase the number of countries in which it is available. Xocova, Xofluza, and cefiderocol are all in-house discovered products, and expanding the presence of these products globally and advancing their growth is one of the most important initiatives in the STS2030 Revision. We will continue to focus on the global expansion of in-house sales capability for internally developed products. Furthermore, as a result of intensive investment in multiple R&D projects, our next growth driver candidates have advanced in clinical development, and we believe that we have built a solid foundation for future growth. In addition to these initiatives, with respect to the HIV franchise partnered with ViiV, we received increasing royalty and dividend income, exceeding previous forecasts, due to the sales growth of innovative long-acting injectable products, such as Cabenuva, and oral two-drug regimens, such as Dovato. We expect continuous medium-to long-term growth of the HIV franchise. As in the previous year, in fiscal 2023 Shionogi also acquired its own shares (10,842,100 shares, the total value of which was approximately 75 billion yen, a record high) and canceled treasury shares (10,840,000 shares, 3.53% of total outstanding shares before cancellation) in order to increase shareholder return and capital efficiency, following its flexible capital policy, aligned with consistent business progress. As a result of the aforementioned progress, and comprehensively considering our current financial condition, and our EPS, DOE, ROE metrics, which are the key shareholder return-indicators in our STS2030 Revision, Shionogi plans to increase its year-end cash dividend by 10 yen per share, revising the previously announced dividend of 75 yen to 85 yen per share. Together with the interim cash dividend, Shionogi will therefore pay annual cash dividends of 160 yen per share, an increase of 25 yen per share from the prior fiscal year, and its annual dividend will have been increased for 12 consecutive years. For Further Information, Contact: SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html

DUBLIN, Aug. 8, 2022 /PRNewswire/ -- The "Natural Killer (NK) Cell Therapeutics Market - A Global and Regional Analysis: Focus on NK Cell Therapy Type, Indication, Country, Pipeline Analysis, and Competitive Landscape - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering. The global NK cell therapeutics market is expected to reach $5,676.1 million in 2032 from $297.2 million in 2024 at a CAGR of 44.59% during the forecast period 2024-2032. The growth in the global NK cell therapeutics market is expected to be driven by the rising in the number of clinical trials and the increasing incidence and prevalence of cancer cases. Market Lifecycle Stage The global NK cell therapeutics market is at a very nascent stage. Currently, there is no approved NK cell therapy in the market. Many biopharmaceutical companies are trying to research and develop new immunotherapies, especially NK cell therapies which would be cost-effective and hence, could act as a next-generation medication for cancer and other acute infectious indications. For instance, major players such as Affimed N.V., GC Cell (GC Biopharma corp.), Glycostem Therapeutics B.V., and Takeda Pharmaceutical Company Limited are investing heavily in clinical trials for their respective therapeutic candidates for various indications such as acute myeloid leukemia (AML), B-cell non-Hodgkin's lymphoma (NHL) - relapsed or refractory, hepatocellular carcinoma (HCC), and peripheral T-cell lymphoma. Increasing funding and investments in research and development is one of the major opportunities in the global NK cell therapeutics market. Impact With an increased worldwide focus on researching NK cell therapies, the major market players are developing novel therapeutics, such as NK cells therapy (unmodified), CAR-NK cells therapy (modified), and NK cell engager. For instance, currently, there are 79 ongoing clinical trials for NK cell therapeutics for different types of indications such as acute myeloid leukemia, hematologic malignancies, hepatocellular carcinoma, and peripheral T-cell lymphoma, which is significantly impacting the growth of NK cell therapeutics market. Immunotherapies are more prominent in countries such as the U.S., the U.K., and South Korea. Moreover, the presence of major market players such as Affimed N.V., Fate Therapeutics, Inc., Gamida Cell Ltd., GC Cell (GC Biopharma corp.), Nkarta, Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited in eight major countries, including the U.S., EU5 (U.K., Germany, France, Spain, Italy), Japan, and South Korea have a positive impact on the market growth. Impact of COVID-19 Due to the pandemic, governments across the globe enforced lockdowns which significantly hampered the research and clinical development of NK cell therapeutics. This situation was majorly witnessed till Q2 2021, which created a negative impact on the global NK cell therapeutics market, resulting in a decline in preclinical and clinical trials of the product candidates. The major reason has been the difficulty in patient recruitment for the ongoing clinical trials, which will have an impact on the launch timelines of the drugs. However, it is worth mentioning here that with the ease of restrictions after Q2 2021, the market for NK cell therapy has gained significant momentum and is anticipated to grow during the forecast period 2024-2032. The COVID-19 pandemic has exerted tremendous strain on the research and clinical development of NK cell therapeutics. Companies operating in the field of NK cell therapies have changed their focus on the research and development of drugs used for COVID-19 treatment to help governments and communities establish a new normal across the globe. This has resulted in the delayed launch of emerging therapies due to a shift in priorities on account of the COVID-19 pandemic. In addition, pharmaceutical companies are diverting their financial resources to develop and repurpose existing drug molecules for the prevention and treatment of COVID-19. This strategy has been adopted by most pharmaceutical companies to generate high revenue from the sale of COVID-19 drugs. These factors exert a combinatorial effect on the development and launch of emerging NK therapies. Market Segmentation In the global NK cell therapeutics market, the NK cell therapy (unmodified) segment is anticipated to dominate the global NK cell therapeutics market during the forecast period and is expected to hold a share of 57.82%. The segment includes the pipeline NK cell therapeutics derived from allogenic or off-the-shelf cancer-killing immunotherapy, which is readily available from cord blood supplies. In 2032, the global NK cell therapeutics market is estimated to be dominated by MG4101 and is expected to hold a 36.35% share of total NK cell therapeutics market, followed by TAK-007 with the market share of 24.20% of the NK cell therapeutics market in 2032. The B-cell non-Hodgkin's lymphoma - relapsed or refractory segment is expected to dominate the global NK cell therapeutics market in 2032 due to the rise in B-cell lymphoma patients across the countries and high unmet need in the disease area. The U.S. NK cell therapeutics market will be valued at $232.4 million in 2024 and is expected to be the leading market contributor. The growth can be attributed to the increased research and development activities in the country. Key Market Players and Competition Synopsis The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, pipeline product portfolio, and market penetration. Some prominent names established in this market are: Affimed N.V. Century Therapeutics, Inc. Celularity Inc. Cytovac A/S Dragonfly Therapeutics, Inc. Fate Therapeutics, Inc. Gamida Cell Ltd. GC Cell (GC Biopharma corp.) Glycostem Therapeutics B.V. ImmunityBio, Inc. Innate Pharma SA Nkarta, Inc. Sanofi S.A. Takeda Pharmaceutical Company Limited VaxCell Biotherapeutics Co., Ltd. Acepodia Inc. iCell Gene Therapeutics Senti Biosciences Shoreline Biosciences Key Topics Covered: 1 Market 1.1 Product Definition 1.2 Inclusion and Exclusion Criteria 1.3 Market Scope 1.3.1 Key Questions Answered 1.4 Research Methodology 1.4.1 Global NK Cell Therapeutics Market: Research Methodology 1.4.2 Primary Data Sources 1.4.3 Secondary Data Sources 1.5 Market Estimation Model 1.6 Criteria for Company Profiling 1.7 Market Overview 1.7.1 Introduction 1.7.2 Evolution of NK Cell Therapeutics 1.7.3 Types of NK Cell Therapeutics 1.7.4 Source of NK Cell Therapeutics 1.7.5 Mechanism of Action: NK Cell Therapies 1.7.5.1 Application of NK Cell Therapeutics in Disease Areas 1.7.5.1.1 Cancer 1.7.5.1.2 Acute Infectious Disease 1.7.6 Role of NK Cell Therapeutics in COVID-19 1.7.7 Comparison between Car T-Cell Therapy and NK Cell Therapy 1.7.8 Advantages and Limitations of NK Cell Therapeutics 1.7.9 Current Market Size and Growth Potential, $Million, 2022-2032 1.7.10 COVID-19 Impact on Global NK Cell Therapeutics Market 1.7.10.1 Overview 1.7.10.2 Research and Clinical Development Interruption in Global NK Cell Therapeutics Market 2 Pipeline Analysis 2.1 Global NK Cell Therapeutics Market Pipeline Analysis 2.2 Probable Potential First Entrants to Global NK Cell Therapeutics Market 2.2.1 Overview 2.2.2 AFM13 2.2.2.1 Product Profile 2.2.2.2 AFM13 Phase II Study Design 2.2.3 MG4101 2.2.3.1 Product Profile 2.2.3.2 MG4101 Phase II Study Design 2.2.4 GTA002 (oNKord) 2.2.4.1 Product Profile 2.2.4.2 GTA002 (oNKord) Phase II Study Design 2.2.5 TAK-007 2.2.5.1 Product Profile 2.2.5.2 TAK-007 Phase II Study Design 3 Industry Analysis 3.1 Overview 3.2 Legal Requirements and Framework in the U.S. 3.2.1 Clinical Trial Authorization 3.2.2 Marketing Authorization 3.2.3 U.S. Food and Drug Administration Guidelines for Biologics License Application (BLA) 3.2.4 Post-Authorization Regulations 3.3 Legal Requirements and Frameworks in Europe 3.4 Legal Requirements and Framework in Japan 3.5 Legal Requirements and Framework in South Korea 3.6 Reimbursement Scenario in the U.S. 3.7 Reimbursement Scenario in Europe 4 Market Dynamics 4.1 Overview 4.2 Impact Analysis 4.3 Market Drivers 4.3.1 Rising Number of Clinical Trials 4.3.2 Increasing Incidence and Prevalence of Cancer 4.4 Market Restraints 4.4.1 Lack of Specificity and Poor In Vivo Survival of the NK Cells 4.4.2 High Cost of Immunotherapy Treatment Associated with Cancer 4.5 Market Opportunities 4.5.1 Increasing Funding and Investment 4.5.2 Rising Number of Partnerships and Collaborations 5 Market Analysis 5.1 Global NK Cell Therapeutics Market (by Therapy Type), $Million, 2024-2032 5.1.1 Overview 5.1.2 NK Cell Therapy (Unmodified) 5.1.3 CAR-NK Cell Therapy (Modified) 5.1.4 NK Cell Engagers 5.2 Global NK Cell Therapeutics Market (by Pipeline Product), $Million, 2024-2032 5.2.1 Overview 5.2.2 AFM13 5.2.3 MG4101 5.2.4 GTA002 (oNKord) 5.2.5 TAK-007 5.3 Global NK Cell Therapeutics Market (by Indication), $Million, 2024-2032 5.3.1 Overview 5.3.2 Acute Myeloid Leukemia 5.3.3 Hepatocellular Carcinoma 5.3.4 Peripheral T-Cell Lymphoma 5.3.5 Relapsed or Refractory (r/r) B-cell Non-Hodgkin's Lymphoma (NHL) 5.4 Global NK Cell Therapeutics Market (by Country), $Million, 2024-2032 5.4.1 Overview 5.4.2 U.S. 5.4.3 U.K. 5.4.4 Germany 5.4.5 France 5.4.6 Italy 5.4.7 Spain 5.4.8 Japan 5.4.9 South Korea 6 Market - Competitive Benchmarking & Company Profiles 6.1 Competitive Landscape 6.1.1 Clinical Developments 6.1.2 Regulatory and Legal Activities 6.1.3 Partnerships and Alliances 6.1.4 Funding Activities 6.1.4.1 Institutional Fundings 6.1.5 Business Expansions 6.2 Company Profiles For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets